Abstract:Abstract Sequences surrounding splice junctions function to recruit splicing elements to promote and suppress the inclusion of an adjacent exon. Mutations disrupting motifs around splice regions and the creation of de novo splice sites have not been functionally characterized genome-wide. Furthermore, many variants that alter the mRNA isoform have been shown to introduce splicing defects, such as premature termination codons (PTCs), which are degraded via nonsense-mediated decay (NMD). Using cancer samples across multiple cancer types, we have the unique opportunity to study the effects of somatic and germline events introduced throughout the genome and with the large dataset provided by The Cancer Genome Atlas (TCGA), we have the power to identify significant events that are influencing mRNA splicing and stability. In this study we aim to characterize splice altering variants (SAVs) and nonsense mutations that directly effect exon inclusion and mRNA degradation, respectively, utilizing the TCGA dataset consisting of both DNA-Seq (whole genome and/or exome sequencing) and RNA-seq from approximately 8,000 tumors representing 24 major cancer types. We have identified 23,615 somatic splice site mutations and 71,009 somatic nonsense mutations in 24 cancer types. For each variant, we have collected the following expression data derived from the RNA-seq: exon, splice junction, isoform, and gene; defining the expression signature of each variant. Expression signatures of known SAVs will facilitate the identification of novel and mis-classified missense and silent mutations affecting splicing. Exploring the distribution of mutations and their correlation with the aforementioned expression data will allow us to establish commonalities and differences that may be indicative of cancer type, molecular subtype, or clinical characteristics. Furthermore our position dependent analysis of nonsense mutations and their correlation with degradation will enhance our ability to determine significant sites influencing mRNA isoform presence. We hypothesize that some intronic/exonic variants outside the canonical splice site will influence exon inclusion and alter the ratio of mRNA isoforms present. Our analysis has identified a number of SAVs, including variants that were mis-classified as missense mutations such as c.190 in BRCA1. The germline coding mutation was found to strengthen a cryptic splice site and discovered to have a higher variant allele fraction in the tumor relative to the normal tissue in two ovarian samples. In conclusion our findings and the continued development of our project will contribute to improving current annotation methods and broaden our understanding of variants that affect splicing and their biological contribution to mRNA isoforms selection in the cell. Citation Format: Reyka G. Jayasinghe, Kuan-lin Huang, Jie Ning, Matthew Wyczalkowski, Charles Lu, Mingchao Xie, Michael Wendl, Michael McLellan, Kai Ye, Li Ding. Pan-Cancer analysis of the effects of splice-altering variants on mRNA splicing and stability. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1929. doi:10.1158/1538-7445.AM2015-1929

Steering research on mRNA splicing in cancer towards clinical translation

RNA splicing dysregulation and the hallmarks of cancer

Dysregulation and therapeutic targeting of RNA splicing in cancer

Splicing Dysregulation in Cancer: from Mechanistic Understanding to a New Class of Therapeutic Targets

Alternative mRNA splicing in cancer immunotherapy

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

Pan-Cancer Analysis Of The Effects Of Splice-Altering Variants On Mrna Splicing And Stability

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

Roles and mechanisms of alternative splicing in cancer — implications for care

Abstract 3139: Pan-cancer splicing analysis reveals shared drivers of malignant transformation and survival

Abstract 1929: Pan-Cancer Analysis of the Effects of Splice-Altering Variants on Mrna Splicing and Stability

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

RNA Splicing Alterations in Lung Cancer Pathogenesis and Therapy

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

Detecting and understanding meaningful cancerous mutations based on computational models of mRNA splicing

Alternative splicing and cancer: a systematic review

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Targeting splicing factors for cancer therapy

In Silico Analysis of a Highly Mutated Gene in Cancer Provides Insight into Abnormal mRNA Splicing: Splicing Factor 3B Subunit 1K700E Mutant